US FDA approves at-home use of BioXcel's agitation drug
TEVA•The FDA approved at-home use of Igalmi for agitation associated with schizophrenia or bipolar disorder. Teva, whose unit acquired nearly all of BioXcel Therapeutics' assets including Igalmi last month, said it will announce commercialization plans later.




